查看购物车
  • Traditional Chinese
  • English
  • Japanese
全球孕产妇保健市场 - 2023-2030
市场调查报告书
商品编码
1352125

全球孕产妇保健市场 - 2023-2030

Global Maternal Health Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

2022年，全球孕产妇保健市场规模达141亿美元，预计2030年将达283亿美元，2023-2030年预测期间复合年增长率为8.5%。

孕产妇保健市场的推动因素包括意识和教育的提高、孕产妇年龄的上升、政府倡议、医疗保健基础设施的不断发展以及孕产妇心理健康的意识。

定期体检、筛检和测试是怀孕期间适当产前护理的一部分。透过及早发现和治疗任何潜在问题，确保母亲和正在成长的胎儿的健康。母亲和未出生孩子的健康取决于良好均衡的饮食。胎儿的生长发育需要摄取足够的必需营养素来支持，这也保护了母亲的健康。

动力学

关键参与者之间日益加强的合作正在推动全球孕产妇保健市场的成长

2023 年 5 月，为了将孕产妇健康和泌尿学领域独特且突破性的产品商业化，CORONA Remedies Private Limited (CORONA) 与 Ferring Pharmaceuticals Pvt. 签订了协议。有限公司（Ferring）是全球生物製药公司 Ferring Pharmaceuticals 的子公司，总部位于瑞士。

CORONA 和 Ferring 之间的合作将为印度各地的患者提供尖端产品，其中一些产品将来自国际品牌，以满足泌尿科和孕产妇健康方面未得到满足的治疗要求。他们很高兴与研究驱动的专业生物製药集团 Ferring 合作，为印度患者提供一流的药物。

孕产妇保健资金的增加推动了全球孕产妇保健市场的成长

2023 年 1 月，位于泰米尔纳德邦韦洛尔的基督教医学院 (CMC) 现在拥有美国国际开发署 (USAID) 提供的先进模拟实验室中心。该实验室将用于培训孕产妇和新生儿护理方面的医疗专业人员，包括心肺復苏术、基础和高级护理技术以及解决孕产妇健康和新生儿紧急情况的最新技术。

美国国际开发署的美国海外学校和医院 (ASHA) 计划提供 100 万美元赠款，资助高级模拟实验室中心。 ASHA 致力于在美国人和印度人之间建立友好和互利的关係。由于病患安全、协议和汇报方法对于学生评估和回馈至关重要，因此该机构在这些领域采用了美国的最佳实践。透过这项努力，美国国际开发署也为医院的新生儿加护病房以及待产室提供了现代化的用品和设备。

孕产妇保健面临的挑战正在阻碍全球孕产妇保健市场的成长

许多地区在获得高品质医疗保健服务方面存在差异，特别是对于服务不足的人群而言，这对孕产妇健康结果产生了负面影响。不良的产前护理可能源于对适当的孕产妇保健缺乏知识和理解，这可能会导致整个怀孕和分娩过程中出现问题。对于许多妇女，特别是低收入或未投保族群来说，高品质孕产妇保健服务（包括产前护理、分娩和产后护理）的费用可能令人望而却步。

目录

第 1 章：方法与范围

  • 研究方法论
  • 报告的研究目的和范围

第 2 章：定义与概述

第 3 章：执行摘要

  • 治疗片段
  • 按指示显示的片段
  • 按配销通路分類的片段
  • 按地区分類的片段

第 4 章：动力学

  • 影响因素
    • 司机
      • 主要参与者之间的合作不断加强
    • 限制
      • 与孕产妇健康相关的挑战
    • 机会
      • 技术进步
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 未满足的需求
  • 监管分析

第 6 章：COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情况
    • COVID-19 期间的情况
    • COVID-19 后的情景
  • COVID-19 期间的定价动态
  • 供需谱
  • 疫情期间政府与市场相关的倡议
  • 製造商的策略倡议
  • 结论

第 7 章：俄罗斯-乌克兰战争分析

第 8 章：人工智慧分析

第 9 章：透过治疗

  • 荷尔蒙
  • 营养品
  • 止痛药
  • 抗感染药
  • 其他的

第 10 章：依指示

  • 流产
  • 早产和分娩
  • 其他的

第 11 章：按配销通路

  • 医院药房
  • 零售药局
  • 网路药局

第 12 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 亚太其他地区
  • 中东和非洲

第13章：竞争格局

  • 竞争场景
  • 产品基准化分析
  • 公司股份分析
  • 主要进展和策略

第 14 章：公司简介

  • Johnson & Johnson
    • 公司简介
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Jiovio Healthcare
  • Pfizer Inc
  • GlaxoSmithKline Inc.
  • Merck & Co., Inc.
  • RAND Corporation
  • SYNAPSE Product Development
  • Siemens
  • Reckitt Benckiser Group Plc
  • Sanofi

第 15 章：附录

简介目录
Product Code: PH6866

Overview

The Global Maternal Health Market reached US$ 14.1 billion in 2022 and is expected to reach US$ 28.3 billion by 2030 growing with a CAGR of 8.5% during the forecast period 2023-2030.

The maternal health market is driven by factors such as increasing awareness and education, rising maternal age, government initiatives, growing healthcare infrastructure and awareness of maternal mental health.

Regular medical check-ups, screenings, and testing are part of proper prenatal care during pregnancy. The health of the mother and the growing fetus is ensured through early detection and treatment of any potential issues. The health of the mother and the unborn child depends on eating a good and balanced diet. The growth and development of the fetus are supported by an adequate intake of necessary nutrients, which also protects the mother's health.

Dynamics

The Increasing Collaboration Among Key Players is Driving the Global Maternal Health Market Growth

In May 2023, in order to commercialize distinctive and ground-breaking products in the areas of Maternal Health & Urology, CORONA Remedies Private Limited (CORONA) entered into an agreement with Ferring Pharmaceuticals Pvt. Ltd. (Ferring), a subsidiary of global biopharmaceuticals company Ferring Pharmaceuticals with headquarters in Switzerland.

The partnership between CORONA and Ferring will provide patients all over India with cutting-edge products, some of which will be from international brands, to meet the unmet treatment requirements in urology and maternal health. They are thrilled to collaborate with Ferring, a research-driven, specialty biopharmaceutical group, to provide patients in India with top-notch medications.

The Increasing Funding for Maternal Health Boost The Global Maternal Health Market Growth

In January 2023, The Christian Medical College (CMC) in Vellore, Tamil Nadu, now has an advanced simulation lab center due to the U.S. Agency for International Development (USAID). The lab will be used to train medical professionals in maternal and neonatal care, including CPR, basic and advanced nursing techniques, and the newest technologies to address maternal health and newborn emergencies.

The American Schools and Hospitals Abroad (ASHA) program of USAID provides a $1 million (USD) grant to fund the Advanced Simulation Lab Center. ASHA works to create friendly and mutually beneficial relationships between Americans and Indians. Since patient safety, protocols, and debriefing methods are crucial for student evaluation and feedback, the institution adopts American best practices in these areas. Modern supplies and equipment for the hospital's neonatal critical care unit and labor and delivery rooms were also made possible by USAID through this effort.

Challenges with Maternal Health are Hampering the Global Maternal Health Market Growth

There are discrepancies in access to high-quality healthcare services in many areas, especially for underserved people, which has a negative impact on maternal health outcomes. Poor prenatal care can stem from a lack of knowledge and understanding about proper maternal health care, which could cause issues throughout pregnancy and childbirth. For many women, particularly in low-income or uninsured populations, the expense of high-quality maternal health services, including prenatal care, delivery, and postnatal care, can be prohibitive.

Segment Analysis

The global maternal health market is segmented based on treatment, indication, distribution channel, and region.

The Hormones Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The hormones segment accounted for the highest market stake accounting for approximately 45.4% of the maternal health market in 2022. Hormones and maternal health are tightly related during pregnancy and the postpartum period. The different physiological and mental changes that take place in a woman's body during pregnancy and after childbirth are significantly regulated by hormones.

For the mother's and the fetus's health to be maintained during pregnancy, specific hormones must be produced in greater quantities. The most notable hormones involved in pregnancy are progesterone, estrogen, human chorionic gonadotropin hormone (hCG), and human placental lactogen (hPL). A hormone called progesterone is essential for preserving the uterine lining and avoiding contractions. Progesterone supplements may occasionally be advised for women who have a history of recurrent miscarriages or who have a short cervix.

Geographical Penetration

North America Holds a Dominant Position in the Global Maternal Health Market

North America is estimated to hold around 1/3rd of the total market share throughout the forecast period. In October 2022, The Special Supplemental Nutrition Program for Women, Infants, and Children, or WIC, has undergone significant modernization and innovation, and the U.S. Department of Agriculture recognizes its accomplishment and promise. The American Rescue Plan Act of 2021 has provided funding for three significant awards totaling about $53 million, as part of the efforts.

Together, these investments will increase the number of eligible women and young children that WIC reaches, improve the level of care that they get throughout their involvement with the program, and assist to close long-standing gaps in maternal and child health.

Competitive Landscape

The major global players in the market include: Johnson & Johnson, Jiovio Healthcare, Pfizer Inc., GlaxoSmithKline Inc., Merck & Co., Inc., RAND Corporation, SYNAPSE Product Development, Siemens, Reckitt Benckiser Group Plc, Sanofi among others.

COVID-19 Impact Analysis

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war may affect the maternal health market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. It may be challenging for expectant mothers to get adequate prenatal and postnatal care if healthcare facilities are damaged or destroyed as a result of the conflict. Conflict zones' hospitals and clinics may be overburdened or unable to deliver proper care.

Artificial Intelligence Analysis:

Artificial intelligence (AI) is increasingly being used in the maternal health market to improve various aspects of data analysis. A pregnant woman's medical history, health information, and lifestyle choices can be analyzed by AI algorithms to identify potential risk factors and forecast difficulties during pregnancy. This enables medical practitioners to develop individualized care regimens and intervene early.

Pregnant women can remotely monitor their health due to wearable technology and mobile apps that are powered by AI. These gadgets can monitor fetal movements, contraction patterns, and other pertinent information, alerting medical professionals if any unsettling trends are found.

By Treatment

  • Hormones
  • Nutritives
  • Analgesics
  • Anti-Infectives
  • Others

By Indication

  • Miscarriage
  • Premature Labor and Birth
  • Others

By Distribution channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In March 2023, MedArrive, the top mobile-integrated care management solution, announced a partnership with Ouma Health, a provider of whole maternity telehealth services, in order to provide complete maternal-fetal care to at-risk women on Medicaid. By including a crucial service into MedArrive's expanding ecosystem of specialized care providers that managed Medicaid health plans can utilize for members in their homes, the collaboration intends to improve the health of expectant mothers and their newborns, particularly those at high risk.

Why Purchase the Report?

  • To visualize the global maternal health market segmentation based on the treatment, indication, distribution channel, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of maternal health market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of critical products of all the major players.

The global maternal health market report would provide approximately 61 tables, 57 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment
  • 3.2. Snippet by Indication
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising collaboration among key players
    • 4.1.2. Restraints
      • 4.1.2.1. Challenges associated with maternal health
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological advancements
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Treatment

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.1.2. Market Attractiveness Index, By Treatment
  • 9.2. Hormones*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Nutritives
  • 9.4. Analgesics
  • 9.5. Anti-Infectives
  • 9.6. Others

10. By Indication

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.1.2. Market Attractiveness Index, By Indication
  • 10.2. Miscarriage*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Premature Labor and Birth
  • 10.4. Others

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.1.2. Market Attractiveness Index, By Distribution Channel
  • 11.2. Hospital Pharmacies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Retail Pharmacies
  • 11.4. Online Pharmacies

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.6.1. U.S.
      • 12.2.6.2. Canada
      • 12.2.6.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.6.1. Germany
      • 12.3.6.2. U.K.
      • 12.3.6.3. France
      • 12.3.6.4. Italy
      • 12.3.6.5. Spain
      • 12.3.6.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.6.1. Brazil
      • 12.4.6.2. Argentina
      • 12.4.6.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.6.1. China
      • 12.5.6.2. India
      • 12.5.6.3. Japan
      • 12.5.6.4. Australia
      • 12.5.6.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Product Benchmarking
  • 13.3. Company Share Analysis
  • 13.4. Key Developments and Strategies

14. Company Profiles

  • 14.1. Johnson & Johnson*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. Jiovio Healthcare
  • 14.3. Pfizer Inc
  • 14.4. GlaxoSmithKline Inc.
  • 14.5. Merck & Co., Inc.
  • 14.6. RAND Corporation
  • 14.7. SYNAPSE Product Development
  • 14.8. Siemens
  • 14.9. Reckitt Benckiser Group Plc
  • 14.10. Sanofi

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us